-
Signature
-
/s/ Lindsey Rolfe
-
Stock symbol
-
CLVS
-
Transactions as of
-
Sep 1, 2022
-
Transactions value $
-
-$3,054
-
Form type
-
4
-
Date filed
-
9/6/2022, 04:15 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
CLVS |
Common Stock |
Options Exercise |
|
+5.06K |
+4.73% |
|
112K |
Sep 1, 2022 |
Direct |
F1 |
transaction |
CLVS |
Common Stock |
Sale |
-$3.05K |
-2.55K |
-2.27% |
$1.20* |
110K |
Sep 2, 2022 |
Direct |
F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
CLVS |
Restricted Stock Units |
Options Exercise |
$0 |
+5.06K |
+11.11% |
$0.00 |
50.6K |
Sep 1, 2022 |
Common Stock |
5.06K |
|
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance